Effects of Tetrahydrolipstatin on Glioblastoma in Mice: MRI-Based Morphologic and Texture Analysis Correlated with Histopathology and Immunochemistry Findings-A Pilot Study.

animal experiment glioblastoma magnetic resonance imaging orlistat tetrahydrolipstatin texture analysis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Apr 2024
Historique:
received: 24 03 2024
revised: 12 04 2024
accepted: 16 04 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

This study aimed to investigate the effects of tetrahydrolipstatin (orlistat) on heterotopic glioblastoma in mice by applying MRI and correlating the results with histopathology and immunochemistry. Human glioblastoma cells were injected subcutaneously into the groins of immunodeficient mice. After tumor growth of >150 mm At histology, all tumors showed high mitotic and proliferative activity (Ki67 ≥ 10%). Reduced fatty acid synthetase expression was measured in the orlistat group ( Orlistat showed effects on heterotopically implanted glioblastoma multiforme in MRI studies of mice based on morphologic and texture analysis.

Sections du résumé

BACKGROUND BACKGROUND
This study aimed to investigate the effects of tetrahydrolipstatin (orlistat) on heterotopic glioblastoma in mice by applying MRI and correlating the results with histopathology and immunochemistry.
METHODS METHODS
Human glioblastoma cells were injected subcutaneously into the groins of immunodeficient mice. After tumor growth of >150 mm
RESULTS RESULTS
At histology, all tumors showed high mitotic and proliferative activity (Ki67 ≥ 10%). Reduced fatty acid synthetase expression was measured in the orlistat group (
CONCLUSIONS CONCLUSIONS
Orlistat showed effects on heterotopically implanted glioblastoma multiforme in MRI studies of mice based on morphologic and texture analysis.

Identifiants

DOI: 10.3390/cancers16081591 PMID: 38672673
pubmed: 38672673
pii: cancers16081591
doi: 10.3390/cancers16081591
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Sabine Wagner (S)

Department of Neuroradiology, Marburg University Hospital, Philipps University, 35043 Marburg, Germany.
Department of Neuroradiology, Institute for Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University, 07747 Jena, Germany.

Christian Ewald (C)

Department of Neurosurgery, Brandenburg Medical School, Campus Brandenburg, 14770 Brandenburg a. d. Havel, Germany.

Diana Freitag (D)

Department of Neurosurgery, Section of Experimental Neurooncology, Jena University Hospital, Friedrich Schiller University, 07747 Jena, Germany.

Karl-Heinz Herrmann (KH)

Medical Physics Group, Institute for Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University, 07743 Jena, Germany.
ORCID: 0000-0003-0757-3525

Arend Koch (A)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité University Medicine, 10117 Berlin, Germany.

Johannes Bauer (J)

Department of Neurosurgery, Brandenburg Medical School, Campus Brandenburg, 14770 Brandenburg a. d. Havel, Germany.

Thomas J Vogl (TJ)

Department of Diagnostic and Interventional Radiology, Goethe University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.
ORCID: 0000-0001-5218-1075

André Kemmling (A)

Department of Neuroradiology, Marburg University Hospital, Philipps University, 35043 Marburg, Germany.

Hubert Gufler (H)

Department of Diagnostic and Interventional Radiology, Goethe University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.

Classifications MeSH